%0 Generic %A Ford, Brian %A Agius, Loranne %D 2020 %T DOM FIGURE 5 Gene expression of Prkaa1 and Prkaa2 is increased by substrate challenge in hepatocytes from vehicle treated mice ex vivo and by chronic treatment with AZD1656 (3mg/kg) for 8 wk. %U https://data.ncl.ac.uk/articles/dataset/DOM_FIGURE_5_Gene_expression_of_Prkaa1_and_Prkaa2_is_increased_by_substrate_challenge_in_hepatocytes_from_vehicle_treated_mice_ex_vivo_and_by_chronic_treatment_with_AZD1656_3mg_kg_for_8_wk_/12550670 %R 10.25405/data.ncl.12550670.v1 %2 https://data.ncl.ac.uk/ndownloader/files/23362931 %K mRNA abundance measurements %K AZD 1656 %K hepatocytes %K Cell Metabolism %X

mRNA levels for Prkaa1 (AMPK-alpha1) and Prkaa2 (AMPK-alpha2) were determined in the experiments described in Fig. 4 in hepatocytes isolated from mice treated for 8-weeks with vehicle or AZD1656 (1 or 3 mg/kg) and then challenged for 4h with the substrates indicated as in Fig. 4I-P. A-B. mRNA levels for Prkaa1 and Prkaa2 normalized to hepatocytes from vehicle treated mice in basal conditions (5mM glucose). C-D. mRNA levels of Prkaa1 and Prkaa2 normalized to the respective controls at 5mM glucose. Means ± SEM, n=4, *P< 0.05 vs respective control (5G); # P < 0.05 vs respective untreated (0 mg/kg).

%I Newcastle University